5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Ischemic O
heart O
disease O
( O
including O
myocardial O
infarction O
) O
and O
stroke O
have O
been O
observed O
in O
patients O
treated O
with O
THALOMID O
in O
combination O
with O
dexamethasone O
. O

( O
5.3 O
) O
* O
Increased O
Mortality O
: O
Observed O
in O
patients O
with O
MM O
when O
pembrolizumab O
was O
added O
to O
dexamethasone O
and O
a O
thalidomide O
analogue O
. O

( O
5.4 O
) O
* O
Drowsiness O
and O
Somnolence O
: O
Instruct O
patients O
to O
avoid O
situations O
where O
drowsiness O
may O
be O
a O
problem O
and O
not O
to O
take O
other O
medications O
that O
may O
cause O
drowsiness O
. O

( O
5.5 O
) O
* O
Peripheral O
Neuropathy O
: O
Examine O
patients O
at O
monthly O
intervals O
for O
the O
first O
3 O
months O
of O
thalidomide O
therapy O
and O
periodically O
thereafter O
for O
signs O
or O
symptoms O
of O
peripheral O
neuropathy O
. O

Consider O
electrophysiological O
testing O
, O
consisting O
of O
measurement O
of O
sensory O
nerve O
action O
potential O
( O
SNAP O
) O
amplitudes O
at O
baseline O
and O
thereafter O
every O
6 O
months O
in O
an O
effort O
to O
detect O
asymptomatic O
neuropathy O
. O

( O
5.6 O
) O
* O
Dizziness O
and O
Orthostatic O
Hypotension O
: O
Advise O
patients O
to O
sit O
upright O
for O
a O
few O
minutes O
prior O
to O
standing O
up O
from O
a O
recumbent O
position O
. O

( O
5.7 O
) O
* O
Neutropenia O
: O
Patients O
may O
require O
dose O
interruption O
and/or O
dose O
reduction O
. O

( O
5.8 O
) O
* O
Thrombocytopenia O
: O
Patients O
may O
require O
dose O
interruption O
and/or O
dose O
reduction O
. O

( O
5.9 O
) O
* O
Increased O
HIV O
Viral O
Load O
: O
Measure O
viral O
load O
after O
the O
first O
and O
third O
months O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

( O
5.10 O
) O
* O
Bradycardia O
: O
Monitor O
patients O
for O
bradycardia O
and O
possible O
syncope O
. O

Dose O
reduction O
or O
discontinuation O
may O
be O
required O
. O

( O
5.11 O
) O
* O
Stevens-Johnson O
Syndrome O
and O
Toxic O
Epidermal O
Necrolysis O
: O
Do O
not O
resume O
THALOMID O
following O
discontinuation O
for O
these O
reactions O
. O

( O
5.12 O
) O
* O
Seizures O
: O
Monitor O
patients O
with O
a O
history O
of O
seizures O
or O
at O
risk O
for O
the O
development O
of O
seizures O
closely O
for O
clinical O
changes O
that O
could O
precipitate O
acute O
seizure O
activity O
. O

( O
5.13 O
) O
* O
Tumor O
Lysis O
Syndrome O
: O
Monitor O
patients O
at O
risk O
( O
e.g. O
, O
those O
with O
high O
tumor O
burden O
prior O
to O
treatment O
) O
and O
take O
appropriate O
precautions O
. O

( O
5.14 O
) O
* O
Hypersensitivity O
: O
Monitor O
patients O
for O
potential O
hypersensitivity O
to O
the O
drug O
and O
its O
components O
. O

( O
5.16 O
) O
5.1 O
Embryo-Fetal O
Toxicity O
Thalidomide O
is O
a O
powerful O
human B-OSE_Labeled_AE
teratogen I-OSE_Labeled_AE
that O
induces O
a O
high O
frequency O
of O
severe O
and O
life-threatening O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
even O
after O
a O
single O
dose O
. O

Mortality B-NonOSE_AE
at O
or O
shortly O
after O
birth O
has O
been O
reported O
in O
about O
40 O
% O
of O
infants O
. O

When O
there O
is O
no O
satisfactory O
alternative O
treatment O
, O
females O
of O
reproductive O
potential O
may O
be O
treated O
with O
thalidomide O
provided O
adequate O
precautions O
are O
taken O
to O
avoid O
pregnancy B-NonOSE_AE
. O

THALOMID O
( O
r O
) O
( O
thalidomide O
) O
is O
only O
available O
through O
the O
THALOMID O
REMS O
program O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Oral O
ingestion O
is O
the O
only O
type O
of O
maternal O
thalidomide O
exposure O
known O
to O
result O
in O
drug-associated O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

There O
are O
no O
specific O
data O
available O
regarding O
the O
reproductive O
risks O
of O
cutaneous O
absorption O
or O
inhalation O
of O
thalidomide O
; O
however O
, O
females O
of O
reproductive O
potential O
should O
avoid O
contact O
with O
THALOMID O
( O
r O
) O
( O
thalidomide O
) O
Capsules O
. O

THALOMID O
Capsules O
should O
be O
stored O
in O
blister O
packs O
until O
ingestion O
. O

If O
there O
is O
contact O
with O
non-intact O
thalidomide O
capsules O
or O
the O
powder O
contents O
, O
the O
exposed O
area O
should O
be O
washed O
with O
soap O
and O
water O
. O

If O
healthcare O
providers O
or O
other O
care O
givers O
are O
exposed O
to O
body O
fluids O
from O
patients O
receiving O
THALOMID O
( O
thalidomide O
) O
the O
exposed O
area O
should O
be O
washed O
with O
soap O
and O
water O
. O

Appropriate O
precautions O
should O
be O
utilized O
, O
such O
as O
wearing O
gloves O
to O
prevent O
the O
potential O
cutaneous O
exposure O
to O
THALOMID O
. O

Females O
of O
Reproductive O
Potential O
Females O
of O
reproductive O
potential O
must O
avoid O
pregnancy B-NonOSE_AE
for O
at O
least O
4 O
weeks O
before O
beginning O
THALOMID O
therapy O
, O
during O
therapy O
, O
during O
dose O
interruptions O
and O
for O
at O
least O
4 O
weeks O
after O
completing O
therapy O
. O

Females O
must O
commit O
either O
to O
abstain O
continuously O
from O
heterosexual O
sexual O
intercourse O
or O
to O
use O
two O
methods O
of O
reliable O
birth O
control O
, O
beginning O
4 O
weeks O
prior O
to O
initiating O
treatment O
with O
THALOMID O
, O
during O
therapy O
, O
during O
dose O
interruptions O
and O
continuing O
for O
4 O
weeks O
following O
discontinuation O
of O
THALOMID O
therapy O
. O

Two O
negative B-NonOSE_AE
pregnancy I-NonOSE_AE
tests I-NonOSE_AE
must O
be O
obtained O
prior O
to O
initiating O
therapy O
. O

The O
first O
test O
should O
be O
performed O
within O
10-14 O
days O
and O
the O
second O
test O
within O
24 O
hours O
prior O
to O
prescribing O
THALOMID O
therapy O
and O
then O
weekly O
during O
the O
first O
month O
, O
then O
monthly O
thereafter O
in O
females O
with O
regular O
menstrual O
cycles O
or O
every O
2 O
weeks O
in O
females O
with O
irregular B-Not_AE_Candidate
menstrual I-Not_AE_Candidate
cycles I-Not_AE_Candidate
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

Males O
Thalidomide B-NonOSE_AE
is I-NonOSE_AE
present I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
semen I-NonOSE_AE
of I-NonOSE_AE
patients I-NonOSE_AE
receiving I-NonOSE_AE
the I-NonOSE_AE
drug I-NonOSE_AE
. O

Therefore O
, O
males O
must O
always O
use O
a O
latex O
or O
synthetic O
condom O
during O
any O
sexual O
contact O
with O
females O
of O
reproductive O
potential O
while O
taking O
THALOMID O
and O
for O
up O
to O
4 O
weeks O
after O
discontinuing O
THALOMID O
, O
even O
if O
they O
have O
undergone O
a O
successful O
vasectomy O
. O

Male O
patients O
taking O
THALOMID O
must O
not O
donate O
sperm O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

Blood O
Donation O
Patients O
must O
not O
donate O
blood O
during O
treatment O
with O
THALOMID O
and O
for O
4 O
weeks O
following O
discontinuation O
of O
the O
drug O
because O
the O
blood O
might O
be O
given O
to O
a O
pregnant O
female O
patient O
whose O
fetus O
must O
not O
be O
exposed O
to O
THALOMID O
. O

5.2 O
THALOMID O
REMS O
Program O
Because O
of O
the O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
risk I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
, O
THALOMID O
is O
available O
only O
through O
a O
restricted O
program O
under O
a O
Risk O
Evaluation O
and O
Mitigation O
Strategy O
( O
REMS O
) O
, O
the O
THALOMID O
REMS O
program O
. O

Required O
components O
of O
the O
THALOMID O
REMS O
program O
include O
the O
following O
: O
* O
Prescribers O
must O
be O
certified O
with O
the O
THALOMID O
REMS O
program O
by O
enrolling O
and O
complying O
with O
the O
REMS O
requirements O
. O

* O
Patients O
must O
sign O
a O
Patient-Physician O
Agreement O
Form O
and O
comply O
with O
the O
REMS O
requirements O
. O

In O
particular O
, O
female O
patients O
of O
reproductive O
potential O
who O
are O
not O
pregnant B-NonOSE_AE
must O
comply O
with O
the O
pregnancy B-NonOSE_AE
testing O
and O
contraception O
requirements O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
and O
males O
must O
comply O
with O
contraception O
requirements O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

* O
Pharmacies O
must O
be O
certified O
with O
the O
THALOMID O
REMS O
program O
, O
must O
only O
dispense O
to O
patients O
who O
are O
authorized O
to O
receive O
THALOMID O
and O
comply O
with O
REMS O
requirements O
. O

Further O
information O
about O
the O
THALOMID O
REMS O
program O
is O
available O
at O
www.celgeneriskmanagement.com O
or O
by O
telephone O
at O
1-888-423-5436 O
. O

5.3 O
Venous O
and O
Arterial O
Thromboembolism O
The O
use O
of O
THALOMID O
in O
patients O
with O
MM B-Not_AE_Candidate
results O
in O
an O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
, O
such O
as O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
. O

This O
risk O
increases O
significantly O
when O
thalidomide O
is O
used O
in O
combination O
with O
standard O
chemotherapeutic O
agents O
including O
dexamethasone O
. O

In O
one O
controlled O
trial O
, O
the O
rate O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
was O
22.5 O
% O
in O
patients O
receiving O
thalidomide O
in O
combination O
with O
dexamethasone O
compared O
to O
4.9 O
% O
in O
patients O
receiving O
dexamethasone O
alone O
( O
p O
= O
0.002 O
) O
. O

Ischemic B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
11.1 O
% O
) O
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( O
1.3 O
% O
) O
, O
and O
stroke B-OSE_Labeled_AE
( O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
2.6 O
% O
) O
have O
also O
occurred O
in O
patients O
with O
previously O
untreated O
MM B-Not_AE_Candidate
treated O
with O
THALOMID O
and O
dexamethasone O
compared O
to O
placebo O
and O
dexamethasone O
( O
4.7 O
% O
, O
1.7 O
% O
, O
and O
0.9 O
% O
, O
respectively O
) O
in O
one O
clinical O
trial O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Consider O
thromboprophylaxis O
based O
on O
an O
assessment O
of O
individual O
patients O
' O
underlying O
risk O
factors O
. O

Patients O
and O
physicians O
should O
be O
observant O
for O
the O
signs O
and O
symptoms O
of O
thromboembolism B-NonOSE_AE
. O

Advise O
patients O
to O
seek O
immediate O
medical O
care O
if O
they O
develop O
symptoms O
such O
as O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
or O
arm B-NonOSE_AE
or O
leg O
swelling I-NonOSE_AE
[ O
see O
Boxed O
Warning O
] O
. O

Agents O
that O
also O
may O
increase O
the O
risk O
of O
thromboembolism B-NonOSE_AE
should O
be O
used O
with O
caution O
in O
patients O
receiving O
THALOMID O
[ O
see O
Drug O
Interactions O
( O
7.7 O
) O
] O
. O

5.4 O
Increased O
Mortality O
in O
Patients O
with O
MM O
When O
Pembrolizumab O
Is O
Added O
to O
a O
Thalidomide O
Analogue O
and O
Dexamethasone O
In O
two O
randomized O
clinical O
trials O
in O
patients O
with O
MM B-Not_AE_Candidate
, O
the O
addition O
of O
pembrolizumab O
to O
a O
thalidomide O
analogue O
plus O
dexamethasone O
, O
a O
use O
for O
which O
no O
PD-1 O
or O
PD-L1 O
blocking O
antibody O
is O
indicated O
, O
resulted O
in O
increased O
mortality B-NonOSE_AE
. O

Treatment O
of O
patients O
with O
MM B-Not_AE_Candidate
with O
a O
PD-1 O
or O
PD-L1 O
blocking O
antibody O
in O
combination O
with O
a O
thalidomide O
analogue O
plus O
dexamethasone O
is O
not O
recommended O
outside O
of O
controlled O
clinical O
trials O
. O

5.5 O
Drowsiness O
and O
Somnolence O
Thalidomide O
frequently O
causes O
drowsiness B-OSE_Labeled_AE
and O
somnolence B-OSE_Labeled_AE
. O

Patients O
should O
be O
instructed O
to O
avoid O
situations O
where O
drowsiness B-NonOSE_AE
may O
be O
a O
problem O
and O
not O
to O
take O
other O
medications O
that O
may O
cause O
drowsiness B-NonOSE_AE
without O
adequate O
medical O
advice O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Advise O
patients O
as O
to O
the O
possible O
impairment B-NonOSE_AE
of O
mental O
and/or O
physical O
abilities O
required O
for O
the O
performance O
of O
hazardous O
tasks O
, O
such O
as O
driving I-NonOSE_AE
a I-NonOSE_AE
car I-NonOSE_AE
or O
operating O
other O
complex O
or O
dangerous O
machinery O
. O

Dose O
reductions O
may O
be O
required O
. O

5.6 O
Peripheral O
Neuropathy O
Thalidomide O
is O
known O
to O
cause O
nerve B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
that O
may O
be O
permanent O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
is O
a O
common O
( O
> O
=10 O
% O
) O
and O
potentially O
severe O
adverse O
reaction O
of O
treatment O
with O
thalidomide O
that O
may O
be O
irreversible O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
generally O
occurs O
following O
chronic O
use O
over O
a O
period O
of O
months O
; O
however O
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
following O
relatively O
short-term O
use O
has O
been O
reported O
. O

The O
correlation O
with O
cumulative O
dose O
is O
unclear O
. O

Symptoms O
may O
occur O
some O
time O
after O
thalidomide O
treatment O
has O
been O
stopped O
and O
may O
resolve O
slowly O
or O
not O
at O
all O
. O

Few O
reports O
of O
neuropathy B-OSE_Labeled_AE
have O
arisen O
in O
the O
treatment O
of O
ENL B-Not_AE_Candidate
despite O
long-term O
thalidomide O
treatment O
. O

However O
, O
the O
inability O
clinically O
to O
differentiate O
thalidomide B-NonOSE_AE
neuropathy I-NonOSE_AE
from O
the O
neuropathy B-NonOSE_AE
often O
seen O
in O
Hansen B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
makes O
it O
difficult O
to O
determine O
accurately O
the O
incidence O
of O
thalidomide B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
neuropathy I-NonOSE_AE
in O
ENL B-Not_AE_Candidate
patients O
treated O
with O
thalidomide O
. O

Patients O
should O
be O
examined O
at O
monthly O
intervals O
for O
the O
first O
3 O
months O
of O
thalidomide O
therapy O
to O
enable O
the O
clinician O
to O
detect O
early O
signs O
of O
neuropathy B-NonOSE_AE
, O
which O
include O
numbness B-NonOSE_AE
, O
tingling O
or O
pain O
in O
the O
hands I-NonOSE_AE
and O
feet O
. O

Patients O
should O
be O
evaluated O
periodically O
thereafter O
during O
treatment O
. O

Patients O
should O
be O
regularly O
counseled O
, O
questioned O
, O
and O
evaluated O
for O
signs O
or O
symptoms O
of O
peripheral B-NonOSE_AE
neuropathy I-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
electrophysiological O
testing O
, O
consisting O
of O
measurement O
of O
sensory O
nerve O
action O
potential O
( O
SNAP O
) O
amplitudes O
at O
baseline O
and O
thereafter O
every O
6 O
months O
in O
an O
effort O
to O
detect O
asymptomatic O
neuropathy O
. O

If O
symptoms O
of O
drug B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
neuropathy I-NonOSE_AE
develop O
, O
thalidomide O
should O
be O
discontinued O
immediately O
to O
limit O
further O
damage O
, O
if O
clinically O
appropriate O
. O

Usually O
, O
treatment O
with O
thalidomide O
should O
only O
be O
reinitiated O
if O
the O
neuropathy B-NonOSE_AE
returns O
to O
baseline O
status O
. O

Medications O
known O
to O
be O
associated O
with O
neuropathy B-NonOSE_AE
should O
be O
used O
with O
caution O
in O
patients O
receiving O
thalidomide O
[ O
see O
Drug O
Interactions O
( O
7.3 O
) O
] O
. O

5.7 O
Dizziness O
and O
Orthostatic O
Hypotension O
Patients O
should O
also O
be O
advised O
that O
thalidomide O
may O
cause O
dizziness B-OSE_Labeled_AE
and O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
that O
, O
therefore O
, O
they O
should O
sit O
upright O
for O
a O
few O
minutes O
prior O
to O
standing O
up O
from O
a O
recumbent O
position O
. O

5.8 O
Neutropenia O
Decreased B-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
, O
including O
neutropenia B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
association O
with O
the O
clinical O
use O
of O
thalidomide O
. O

Treatment O
should O
not O
be O
initiated O
with O
an O
absolute B-Not_AE_Candidate
neutrophil I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
ANC I-Not_AE_Candidate
) I-Not_AE_Candidate
of I-Not_AE_Candidate
< I-Not_AE_Candidate
7 I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
. O

White O
blood O
cell O
count O
and O
differential O
should O
be O
monitored O
on O
an O
ongoing O
basis O
, O
especially O
in O
patients O
who O
may O
be O
more O
prone O
to O
neutropenia B-Not_AE_Candidate
, O
such O
as O
patients O
who O
are O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
. O

If O
ANC B-NonOSE_AE
decreases I-NonOSE_AE
to I-NonOSE_AE
below I-NonOSE_AE
7 I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
while O
on O
treatment O
, O
the O
patient O
's O
medication O
regimen O
should O
be O
re-evaluated O
and O
, O
if O
the O
neutropenia B-NonOSE_AE
persists O
, O
consideration O
should O
be O
given O
to O
withholding O
thalidomide O
if O
clinically O
appropriate O
. O

5.9 O
Thrombocytopenia O
Thrombocytopenia B-OSE_Labeled_AE
, O
including O
Grade O
3 O
or O
4 O
occurrences O
, O
has O
been O
reported O
in O
association O
with O
the O
clinical O
use O
of O
thalidomide O
. O

Monitor O
blood O
counts O
, O
including O
platelet O
counts O
. O

Dose O
reduction O
, O
delay O
, O
or O
discontinuation O
may O
be O
required O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
bleeding B-NonOSE_AE
including O
petechiae B-NonOSE_AE
, O
epistaxis B-NonOSE_AE
, O
and O
gastrointestinal B-NonOSE_AE
bleeding I-NonOSE_AE
, O
especially O
if O
concomitant O
medication O
may O
increase O
the O
risk O
of O
bleeding B-NonOSE_AE
. O

5.10 O
Increased O
HIV O
Viral O
Load O
In O
a O
randomized O
, O
placebo-controlled O
trial O
of O
thalidomide O
in O
an O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
patient O
population O
, O
plasma B-OSE_Labeled_AE
HIV I-OSE_Labeled_AE
RNA I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
were O
found O
to O
increase I-OSE_Labeled_AE
( O
median O
change O
= O
0.42 O
log10copies O
HIV O
RNA/mL O
, O
p O
= O
0.04 O
compared O
to O
placebo O
) O
. O

A O
similar O
trend O
was O
observed O
in O
a O
second O
, O
unpublished O
study O
conducted O
in O
patients O
who O
were O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
. O

The O
clinical O
significance O
of O
this O
increase O
is O
unknown O
. O

Both O
studies O
were O
conducted O
prior O
to O
availability O
of O
highly O
active O
antiretroviral O
therapy O
. O

Until O
the O
clinical O
significance O
of O
this O
finding O
is O
further O
understood O
, O
in O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
patients O
, O
viral O
load O
should O
be O
measured O
after O
the O
first O
and O
third O
months O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

5.11 O
Bradycardia O
Bradycardia B-OSE_Labeled_AE
in O
association O
with O
thalidomide O
use O
has O
been O
reported O
. O

Cases O
of O
bradycardia B-OSE_Labeled_AE
have O
been O
reported O
, O
some O
required O
medical O
interventions O
. O

The O
clinical O
significance O
and O
underlying O
etiology O
of O
the O
bradycardia B-NonOSE_AE
noted O
in O
some O
thalidomide-treated O
patients O
are O
presently O
unknown O
. O

Monitor O
patients O
for O
bradycardia B-NonOSE_AE
and O
syncope B-NonOSE_AE
. O

Dose O
reduction O
or O
discontinuation O
may O
be O
required O
. O

Medications O
known O
to O
decrease B-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
should O
be O
used O
with O
caution O
in O
patients O
receiving O
thalidomide O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.12 O
Stevens-Johnson O
Syndrome O
and O
Toxic O
Epidermal O
Necrolysis O
Serious O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
which O
may O
be O
fatal B-NonOSE_AE
, O
have O
been O
reported O
. O

THALOMID O
should O
be O
discontinued O
if O
a O
skin B-NonOSE_AE
rash I-NonOSE_AE
occurs O
and O
only O
resumed O
following O
appropriate O
clinical O
evaluation O
. O

If O
the O
rash B-NonOSE_AE
is O
exfoliative O
, O
purpuric O
, O
or O
bullous I-NonOSE_AE
or O
if O
Stevens B-NonOSE_AE
- I-NonOSE_AE
Johnson I-NonOSE_AE
syndrome I-NonOSE_AE
or O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
is O
suspected O
, O
use O
of O
THALOMID O
should O
not O
be O
resumed O
. O

5.13 O
Seizures O
Although O
not O
reported O
from O
pre-marketing O
controlled O
clinical O
trials O
, O
seizures B-OSE_Labeled_AE
, O
including O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsions I-OSE_Labeled_AE
, O
have O
been O
reported O
during O
post-approval O
use O
of O
THALOMID O
in O
clinical O
practice O
. O

Because O
these O
events O
are O
reported O
voluntarily O
from O
a O
population O
of O
unknown O
size O
, O
estimates O
of O
frequency O
can O
not O
be O
made O
. O

Most O
patients O
had O
disorders O
that O
may O
have O
predisposed O
them O
to O
seizure B-NonOSE_AE
activity O
, O
and O
it O
is O
not O
currently O
known O
whether O
thalidomide O
has O
any O
epileptogenic B-NonOSE_AE
influence O
. O

During O
therapy O
with O
thalidomide O
, O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
or O
with O
other O
risk O
factors O
for O
the O
development O
of O
seizures B-NonOSE_AE
should O
be O
monitored O
closely O
for O
clinical O
changes O
that O
could O
precipitate O
acute O
seizure B-NonOSE_AE
activity O
. O

5.14 O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
Monitor O
patients O
at O
risk O
of O
tumor B-NonOSE_AE
lysis I-NonOSE_AE
syndrome I-NonOSE_AE
( O
e.g. O
, O
patients O
with O
high O
tumor B-Not_AE_Candidate
burden O
prior O
to O
treatment O
) O
and O
take O
appropriate O
precautions O
. O

5.15 O
Contraceptive O
Risks O
Some O
contraceptive O
methods O
may O
pose O
a O
higher O
risk O
of O
adverse O
effects O
or O
may O
be O
medically O
contraindicated O
in O
some O
patients O
treated O
with O
THALOMID O
. O

Because O
some O
patients O
may O
develop O
sudden O
, O
severe O
neutropenia B-NonOSE_AE
and/or O
thrombocytopenia B-NonOSE_AE
, O
use O
of O
an O
intrauterine O
device O
( O
IUD O
) O
or O
implantable O
contraception O
in O
these O
patients O
may O
carry O
an O
increased O
risk O
for O
infection B-NonOSE_AE
or O
bleeding B-NonOSE_AE
either O
at O
insertion O
, O
removal O
or O
during O
use O
. O

Treatment O
with O
THALOMID O
, O
the O
presence O
of O
an O
underlying O
malignancy B-Not_AE_Candidate
, O
and/or O
use O
of O
an O
estrogen-containing O
contraceptive O
can O
each O
increase O
the O
risk O
of O
thromboembolism B-OSE_Labeled_AE
. O

It O
is O
not O
known O
if O
these O
risks O
of O
thromboembolism B-NonOSE_AE
are O
additive O
. O

However O
, O
they O
should O
be O
taken O
into O
consideration O
when O
choosing O
contraceptive O
methods O
. O

5.16 O
Hypersensitivity O
Hypersensitivity B-OSE_Labeled_AE
to O
THALOMID O
has O
been O
reported O
. O

Signs O
and O
symptoms O
have O
included O
the O
occurrence O
of O
erythematous B-NonOSE_AE
macular I-NonOSE_AE
rash I-NonOSE_AE
, O
possibly O
associated O
with O
fever B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
, O
and O
if O
severe O
, O
may O
necessitate O
interruption O
of O
therapy O
. O

If O
the O
reaction O
recurs O
when O
dosing O
is O
resumed O
, O
THALOMID O
should O
be O
discontinued O
. O

